Portfolio company news

All Group media enquiries should be directed to
Vanessa Maydon, Corporate Affairs Director.

Cinven Partners LLP
Warwick Court
Paternoster Square
London EC4M 7AG

 

Tel: +44 (0)20 7661 3325
Mob: +44 (0)7802 961 902
Email: Vanessa Maydon

Press releases

Sebia
17 December 2014

Cinven sells Sebia to Montagu Private Equity and Astorg Partners

Cinven today announces the completion of the sale of Sebia, the in-vitro diagnostics protein testing business, to Montagu Private Equity and Astorg Partners for €1.4bn. This follows the announcement in June that Cinven had entered into exclusive negotiations with a consortium led by these two companies.

Cinven acquired Sebia in June 2010 and this transaction represents a 2.4x return on Cinven's original investment. During Cinven's ownership Sebia has extended its operations into the US and emerging markets which has led to significant revenue increase, also positioning Sebia as a clear global leader within the in-vitro diagnostics market. Throughout this period the Company also launched major products such as a diabetes test and is in the process of launching a new generation of Capillary instrument to provide strong future earnings growth.

Cinven's successful investment in Sebia follows its investment in Phadia, the in-vitro diagnostics allergy testing business, which generated a 3.4x multiple on Cinven's original investment, following the sale of the business to Thermo Fisher Scientific, Inc.